112623-19-5

Basic information

• Product Name: cis-3-(Hydroxymethyl)cyclobutanol
• Synonyms: cyclobutanemethanol, 3-hydroxy-, cis-
• CAS NO: 112623-19-5
• Molecular Formula: C₅H₁₀O₂
• Molecular Weight: 102.1317
• Mol File: 112623-19-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 234.123°C at 760 mmHg
• Flash Point: 115.907°C
• Density: 1.18g/cm³
• Vapor Pressure: 0.01mmHg at 25°C
• Refractive Index: 1.519
• CAS DataBase Reference: cis-3-(Hydroxymethyl)cyclobutanol(CAS DataBase Reference)
• NIST Chemistry Reference: cis-3-(Hydroxymethyl)cyclobutanol(112623-19-5)
• EPA Substance Registry System: cis-3-(Hydroxymethyl)cyclobutanol(112623-19-5)

Safety Data

• Hazardous Substances Data: 112623-19-5(Hazardous Substances Data)

Upstream product

• 4934-99-0 methylester of 3-hydroxycyclobutane-1-carboxylic acid 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 695-95-4 methyl 3-oxocyclobutanecarboxylate 

Downstream Products

• 1394119-83-5 (3-((tert-butyldimethylsilyl)oxy)cyclobutyl)methanol 
• 1245647-19-1 3-(((tert-butyldimethylsilyl)oxy)methyl)cyclobutan-1-ol 
• 1544740-13-7 3-((4-bromo-3,5-dimethylphenoxy)methyl)cyclobutanol 
• 1544740-14-8 3-((4-bromo-3,5-dimethylphenoxy)methyl)cyclobutanone 
• 1544740-15-9 2-bromo-5-((3,3-difluorocyclobutyl)methoxy)-1,3-dimethylbenzene 
• 1356924-73-6 (3-hydroxycyclobutyl)methyl 4-methylbenzenesulfonate 

Relevant articles and documents

FLAVONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE

The present invention provides flavone derivatives having the general formula (I) which are useful for the treatment of Hepatitis B Virus infection (HBV). The compounds act as cccDNA (covalently closed circular DMA) inhibitors.

ANTIBACTERIAL AGENTS

Antibacterial compounds of formula (I) are provided, as well as stereoisomers and pharmaceutically acceptable salts and esters thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.